Table 1.

Clinical characteristics of primary AML patient samples used for RNA sequencing

	Pre-chemotherapy							Post-chemotherapy
BBa	Age range	Sex	WHO (2016)	WCC	Karyotypeb	Sample	Inductionc	Response	Sample	Blast %e	Days since start of Rx	Outcome
64	40–59	M	AML with inv.(3)	14.1	Inv(3)	PB	ADE + GO	Borderline refractory with persistent cytogenetic abnormality	BM	5%	33	Relapsed and died following HSCTf
121	16–39	F	AML with inv.(3)	6.5	Inv(3)	BM	DA + GO	Refractory	BM	30%	20	Transient remission with salvage therapy; then relapsed and died
205	40–59	F	Therapy-related myeloid neoplasm (t-AML)	12.6	Monosomal	PB	DA (90) FLAG-IDA4	Refractory	BM	12%	62d	Relapsed and died following HSCTf
285	60–79	M	AML with myelodysplasia-related changes	3.9	Normal	PB	DA	Refractory	BM	30%	32	Induction failure; died
349	40–59	M	AML, not otherwise specified	2.4	Normal	BM	DA	Refractory	BM	70%	38	Transient remission with salvage therapy; then relapsed and died
494	60–79	M	AML, not otherwise specified	30.2	Monosomal	BM	DA	Refractory	BM	58%	32	Induction failure; died

^aBiobank identifier

^bSee Table 2 for details

^cInduction regimes: ADE Cytarabine, Daunorubicin, Etoposide; GO Gemtuzumab ozogamycin; DA Daunorubicin (standard dose 60 mg/m², patient 205 received 90 mg/m² as part of a clinical trial), Cytarabine; FLAG-IDA Fludarabine, Cytarabine, G-CSF, Idarubicin

^dThe post treatment sample for patient 205 was collected after a second cycle of chemotherapy. All other post-treatment samples were collected following induction chemotherapy

^eBlast percentage following treatment as determined by clinical service flow cytometry (FC). FC not performed for sample 64 2 M; results are shown for trephine histopathology (5%)

^fHSCT performed in the presence of persistent cytogenetic abnormality but morphological remission

WCC, white cell count (× 10⁹/l); PB, peripheral blood; BM, bone marrow; HSCT, hematopoietic stem cell transplantation; Rx, treatment